warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Stroke

Conditions

Stroke, Atrial Fibrillation, Embolism

Trial Timeline

Nov 1, 2008 → May 1, 2013

NCT ID

NCT00781391

About warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban

warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban is a phase 3 stage product being developed by Daiichi Sankyo for Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00781391. Target conditions include Stroke, Atrial Fibrillation, Embolism.

What happened to similar drugs?

13 of 20 similar drugs in Stroke were approved

Approved (13) Terminated (6) Active (4)

✅StatinShionogiApproved

✅AlteplaseKyowa KirinApproved

✅RepathaAmgenApproved

✅DonepezilPfizerApproved

✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved

✅Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Mochida PharmaceuticalApproved

✅Clopidogrel + Clopidogrel placebo + AspirinBristol Myers SquibbApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00781391	Phase 3	Completed	Nov 1, 2008	May 1, 2013	Stroke

Competing Products

20 competing products in Stroke

See all competitors

Product	Company	Stage	Hype Score
SPT-07A injection	Sinopharm	Phase 3	36
Osmotic drugs	Sinopharm	Pre-clinical	33
Aspirin, Clopidogrel	Yuhan	Pre-clinical	26
DS-1040b + Placebo	Daiichi Sankyo	Phase 1/2	32
SUN13837 + placebo	Daiichi Sankyo	Phase 2	27
DS-1040b + Aspirin	Daiichi Sankyo	Phase 1	29
piclozotan low dose + placebo + piclozotan high dose	Daiichi Sankyo	Phase 2	27
DS1040b + Placebo	Daiichi Sankyo	Pre-clinical	26
Pharmacological intensification based on olmesartan	Daiichi Sankyo	Phase 2	35
YM872 (zonampanel), t-PA (alteplase)	Astellas Pharma	Phase 2	35
ASP2246	Astellas Pharma	Phase 1/2	39
Neu2000KWL + Neu2000KWL + Neu2000KWL + Placebos	Sun Pharmaceutical	Phase 2	35
XY03-EA + XY03-EA Placebo	Sun Pharmaceutical	Phase 2	31
Redasemtide + Placebo	Shionogi	Phase 2	39
Statin	Shionogi	Approved	43
Alteplase	Kyowa Kirin	Approved	43
ONO-2506 + ONO-2506 + ONO-2506	Ono Pharmaceutical	Phase 2/3	38
Abciximab	Eli Lilly	Phase 3	32
Abciximab	Eli Lilly	Phase 3	32
SB623 Implant (2.5M) + SB623 Implant (5.0M)	Sumitomo Pharma	Phase 2	35